{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:58:13Z","timestamp":1792760293229,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ygyno.2019.06.014","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T08:41:36Z","timestamp":1561106496000},"page":"539-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II\/III trials of NOGGO metadata base"],"prefix":"10.1016","volume":"154","author":[{"given":"E.","family":"Canaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.I.","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Chekerov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.06.014_bb0005","unstructured":"Shih Ie, M. and R.J. Kurman, Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol., 2004. 164(5): p. 1511\u20138."},{"issue":"11","key":"10.1016\/j.ygyno.2019.06.014_bb0010","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/PAS.0b013e31816fd555","article-title":"Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data","volume":"32","author":"Vang","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"issue":"12","key":"10.1016\/j.ygyno.2019.06.014_bb0015","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/bjc.2011.455","article-title":"Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers","volume":"105","author":"Braicu","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2019.06.014_bb0020","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1081\/CNV-200032761","article-title":"Ovarian cancer: review of the National Institute for clinical excellence (NICE) guidance recommendations","volume":"22","author":"Johnston","year":"2004","journal-title":"Cancer Investig."},{"issue":"4","key":"10.1016\/j.ygyno.2019.06.014_bb0025","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ygyno.2019.06.014_bb0030","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-04-0297","article-title":"Raf kinase as a target for anticancer therapeutics","volume":"4","author":"Sridhar","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2019.06.014_bb0035","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.06.014_bb0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2019.06.014_bb0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO study group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"2 Pt 1","key":"10.1016\/j.ygyno.2019.06.014_bb0050","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Fader","year":"2013","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.06.014_bb0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"29","author":"Colombo","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2019.06.014_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2019.06.014_bb0065","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the north-eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"26","author":"Sehouli","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.06.014_bb0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian Cancer: a randomized multicenter phase II trial of the north-eastern German society of gynecological oncology ovarian Cancer study group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2019.06.014_bb0075","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1093\/annonc\/mdw418","volume":"27","author":"Sehouli","year":"2016","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2019.06.014_bb0080","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2019.06.014_bb0085","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00432-016-2307-0","article-title":"A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the north-eastern German Society of Gynecological Oncology (NOGGO)","volume":"143","author":"Sehouli","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2019.06.014_bb0090","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/IGC.0000000000000477","article-title":"Should all cases of high-grade serous ovarian, tubal, and primary peritoneal carcinomas be reclassified as Tubo-ovarian serous carcinoma?","volume":"25","author":"Moss","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2019.06.014_bb0095","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment","volume":"22","author":"Hess","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.06.014_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.06.014_bb0105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.06.014_bb0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.humpath.2018.10.020","article-title":"Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor Bank ovarian Cancer network","volume":"85","author":"Sehouli","year":"2019","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.06.014_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2019.06.014_bb0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1525-1438.2007.00820.x","article-title":"Differences of chemoresistance assay between invasive micropapillary\/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma","volume":"17","author":"Santillan","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2019.06.014_bb0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2014.11.005","article-title":"The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","volume":"136","author":"Crane","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.06.014_bb0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.06.014_bb0135","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.ygyno.2019.06.014_bb0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/01443615.2017.1336613","article-title":"Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer","volume":"38","author":"Katsnelson","year":"2018","journal-title":"J. Obstet. Gynaecol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.06.014_bb0145","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian Cancer consensus conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2019.06.014_bb0150","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2019.06.014_bb0155","doi-asserted-by":"crossref","unstructured":"du Bois A, V.I., Ferron G, Reuss A, Meier W, Greggi S et al., Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J. Clin. Oncol. 2017(35(Suppl). (abstract 5501)).","DOI":"10.1200\/JCO.2017.35.15_suppl.5501"},{"issue":"4","key":"10.1016\/j.ygyno.2019.06.014_bb0160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ajog.2008.01.035","article-title":"Epidemiology of low-grade serous ovarian cancer","volume":"198","author":"Plaxe","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.06.014_bb0165","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.25460","article-title":"Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study","volume":"117","author":"Zaino","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2019.06.014_bb0170","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ygyno.2009.02.010","article-title":"Clinicopathological characteristics of mucinous adenocarcinoma of the ovary","volume":"113","author":"Shimada","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.06.014_bb0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10147-013-0522-0","article-title":"Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer","volume":"19","author":"Kajiyama","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.06.014_bb0180","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2407-8-252","article-title":"Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study","volume":"8","author":"Pignata","year":"2008","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2019.06.014_bb0185","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/IGC.0b013e31823eed2c","article-title":"Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type?","volume":"22","author":"Kajiyama","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2019.06.014_bb0190","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2003.09.030","article-title":"In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer","volume":"92","author":"Cloven","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2019.06.014_bb0195","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/IGC.0b013e3182a01813","article-title":"Specialized pathology review in patients with ovarian cancer: results from a prospective study","volume":"23","author":"Kommoss","year":"2013","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819313277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819313277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:33:24Z","timestamp":1568334804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819313277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0090825819313277"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.06.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II\/III trials of NOGGO metadata base","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}